C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of$ 0.44. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.36%. A quarter ago, it was expected that this company would post a loss of$ 0.40 per share when it actually produced a loss of $0.35, delivering a surprise of 12.50%.Over the last four quarters, the company has s ...